The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 28, 2023
Filed:
Aug. 30, 2019
Applicant:
Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);
Inventors:
Carrie Brownstein, New York, NY (US);
Israel Lowy, Dobbs Ferry, NY (US);
Lieve Lucille Adriaens, Westfield, NJ (US);
Assignee:
Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 31/405 (2006.01); A61K 31/573 (2006.01); A61K 45/06 (2006.01); C07K 16/24 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/3955 (2013.01); A61K 31/405 (2013.01); A61K 31/573 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 16/248 (2013.01); C07K 16/2809 (2013.01); C07K 16/2818 (2013.01); C07K 16/2866 (2013.01); C07K 16/2887 (2013.01); A61K 2039/507 (2013.01); A61K 2039/545 (2013.01); C07K 2317/31 (2013.01);
Abstract
Administration regimens for therapeutic proteins (e.g., T cell-activating bispecific antibodies) that mitigate cytokine release syndrome and infusion-related reaction are disclosed. The methods employ initial fractional dosing with optional administration of additional agents such as steroids or cytokine antagonists that are discontinued with maximal weekly dosing over the course of the dosing regimen.